Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ALLG LY-02 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Australasian Leukaemia and Lymphoma Group | OTHER |
| Australasian Radiation Oncology Lymphoma Group | OTHER |
| Wesley Research Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial is intended to determine the results obtained when standard treatment for Non Hodgkin's lymphoma is applied to the disease in a rare subtype which arises in bone. Patients in the study undergo a detailed assessment, then treatment with chemotherapy and radiotherapy, followed by close monitoring.
Patients with non-Hodgkin's lymphoma arising primarily in bone have been studied using a number of different names making literature searching difficult. The term Osteolymphoma has been proposed to make searching easier in the future. Patients in this study undergoing staging which includes isotope bone scanning and PET scanning where available. Eligible patients then undergo treatment with three cycles of CHOP chemotherapy at conventional doses and shrinking field radiotherapy to a total of 45 Gy. Monoclonal antibodies are not included as good results have been obtained without using them. After treatment the patients are regularly monitored. The trial is presented twice per year at the meetings of TROG, ALLG and AROLG.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone. | Drug | Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2 |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival. The time from registration to the date of death | Main analysis when accrual is complete at approx. 10 years. |
| Measure | Description | Time Frame |
|---|---|---|
| Time to local or regional failure. Measured from registration. | Main analysis when accrual is complete at approx. 10 years. | |
| Pathological fracture rate. Measured from registration. | Main analysis when accrual is complete at approx. 10 years. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Christie, FRANZCR | East Coasr Cancer Centre | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Prince Alfred Hospital | Camperdown | New South Wales | 2050 | Australia | ||
| Liverpool Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 17894765 | Background | Christie DR, Gabriel GS, Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J. 2007 Oct;37(10):680-6. doi: 10.1111/j.1445-5994.2007.01451.x. | |
| 19527368 | Result | Christie D, Le T, Watling K, Cornes D, O'Brien P, Hitchins R. Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02). J Med Imaging Radiat Oncol. 2009 Apr;53(2):203-6. doi: 10.1111/j.1754-9485.2009.02054.x. |
| Label | URL |
|---|---|
| Click here for more information about this study on the TROG official website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Radiotherapy | Radiation | Total 45 Gy in 25 fractions |
|
|
| Liverpool |
| New South Wales |
| 1871 |
| Australia |
| Calvary Mater Newcastle | Newcastle | New South Wales | 2310 | Australia |
| Westmead Hospital | Wentworthville | New South Wales | 2145 | Australia |
| Wollongong Hospital | Wollongong | New South Wales | Australia |
| The Wesley Radiation Oncology Pty Ltd | Auchenflower | Queensland | 4006 | Australia |
| Royal Brisbane Hospital | Herston | Queensland | 4029 | Australia |
| Mater QRI | South Brisbane | Queensland | 4101 | Australia |
| North Queensland Oncology Service | Townsville | Queensland | 4810 | Australia |
| East Coast Cancer Centre, John Flynn Hospital | Tugun | Queensland | 4224 | Australia |
| Princess Alexandra Hospital | Woolloongabba | Queensland | 4102 | Australia |
| Royal Adelaide Hospital | Adelaide | South Australia | 5000 | Australia |
| Royal Hobart Hospital | Hobart | Tasmania | 7000 | Australia |
| Launceston General Hospital | Launceston | Tasmania | 7250 | Australia |
| Peter MacCallum Cancer Centre | East Melbourne | Victoria | 3002 | Australia |
| Andrew Love Cancer Care Centre, Geelong Hospital | Geelong | Victoria | 3220 | Australia |
| Sir Charles Gairdner Hospital | Nedlands | Western Australia | 6009 | Australia |
| Auckland Hospital | Auckland | 1001 | New Zealand |
| Waikato Hospital | Hamilton | 3200 | New Zealand |
| Palmerston North Hospital | Palmerston North | New Zealand |
| 20638196 | Derived | Christie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G. Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1164-70. doi: 10.1016/j.ijrobp.2010.03.036. Epub 2010 Jul 16. |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003520 | Cyclophosphamide |
| D004317 | Doxorubicin |
| D014750 | Vincristine |
| D011239 | Prednisolone |
| C506643 | liposomal doxorubicin |
| D011878 | Radiotherapy |
| D011827 | Radiation |
| ID | Term |
|---|---|
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D003630 | Daunorubicin |
| D018943 | Anthracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D011083 | Polycyclic Compounds |
| D000617 | Aminoglycosides |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D014748 | Vinca Alkaloids |
| D046948 | Secologanin Tryptamine Alkaloids |
| D026121 | Indole Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D054836 | Indolizidines |
| D007212 | Indolizines |
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D013812 | Therapeutics |
| D055585 | Physical Phenomena |
Not provided
Not provided